Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Talazoparib and Palbociclib Axitinib or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors TalaCom Trial

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating patients

  • 0 views
  • 27 Nov, 2021
  • 1 location
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a

cardiac arrhythmia
tumor cells
neutrophil count
adjuvant chemotherapy
ct scan
  • 433 views
  • 25 Jan, 2021
  • 1093 locations
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or

measurable disease
ROS1
probe
pleural effusion
ros1 rearrangement
  • 0 views
  • 19 Mar, 2021
A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.

measurable disease
ROS1
cancer chemotherapy
crizotinib
brain metastases
  • 5 views
  • 01 Jul, 2021
  • 1 location
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety

measurable disease
malignant melanoma of skin
solid tumour
cancer
  • 42 views
  • 11 Feb, 2022
  • 11 locations
Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance (ERSGATR)

different mutation sites .Phase I/II clinical trials in the US of ensatinib showed ORR of 25% (4/16) in patients previously treated with crizotinib and second-generation ALK-TKI (N=16) .In the phase II

  • 0 views
  • 21 Mar, 2022
  • 1 location
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …

  • 0 views
  • 18 Feb, 2021
  • 1 location
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

ifosfamide
cancer
cytarabine
imatinib
etoposide
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.

ROS1
alopecia
serum bilirubin level
cancer chemotherapy
crizotinib
  • 0 views
  • 27 Jun, 2021
  • 1 location
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

  • 0 views
  • 19 Jun, 2021
  • 30 locations